Ethyl 2-(1-Imidazolyl)acetate

We are Ethyl 2-(1-Imidazolyl)acetate CAS:17450-34-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    Ethyl 2-(1-Imidazolyl)acetate
CAS.NO: 17450-34-9
Synonyms: 
Ethyl 1H-imidazol-1-ylacetate
Ethyl 2-(1H-imidazol-1-yl)acetate
Ethyl 1H-imidazole-1-acetate

Molecular Formula: C7H10N2O2
Molecular Weight:154.16600

Physical and Chemical Properties:
Density: 1.14g / cm3
Boiling point: 293ºC at 760 mmHg
Flash point: 131ºC
Refractive index: 1.524

Specification:
Appearance: white powder
Purity:≥99%
Moisture Content: 0.25%
Impurity: 0.30%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Zoledronic acid  CAS:118072-93-8

Related News: The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels.N- (2-oxo-1H-pirimidin-6-il) benzamida CAS:26661-13-2 Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.Isobutyl Chloroformate Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.2-Chloro-6-fluorotoluene The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.